Technical Analysis for SMMT - Summit Therapeutics plc
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 3.50 | -0.28% | -0.01 |
Earnings due: May 9
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Stochastic Buy Signal | Bullish | 0.00% | |
Lizard Bullish | Bullish Day Trade Setup | 0.00% | |
Doji - Bullish? | Reversal | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Oversold Stochastic | Weakness | -0.28% | |
Narrow Range Bar | Range Contraction | -1.96% | |
Doji - Bullish? | Reversal | -1.96% | |
Outside Day | Range Expansion | -1.96% | |
Oversold Stochastic | Weakness | -1.96% | |
MACD Bearish Signal Line Cross | Bearish | -1.13% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 6 hours ago |
Up 1% | about 8 hours ago |
Down 3% | about 8 hours ago |
Fell Below Previous Day's Low | about 8 hours ago |
Down 2 % | about 8 hours ago |
Get a Trading Assistant
- Earnings date: 05/09/2024
Summit Therapeutics plc Description
Summit Corporation plc, a drug discovery and development company, engages in the discovery and development of novel drug candidates to treat areas of high unmet medical need. The company licenses its drug discovery platform, known as Seglin technology, for the identification of new drug leads and candidates with the potential to target a range of diseases. Its pipeline consists of clinical stage programmes targeting Duchenne Muscular Dystrophy (DMD) and Clostridium difficile infection (CDI). The company provides SMT C1100, a small molecule Utrophin modulator for DMD patients that has completed Phase I clinical trial; and SMT 19969, a Phase I clinical trial completed novel molecule antibiotic for the treatment for initial CDI and prevention of recurrent disease. It is also engaged in other programmes that include OGA inhibitor programme for the treatment of dementia. The company has a technology license agreement with Bristol-Myers Squibb to access the Seglin technology platform. It has operations primarily in the United Kingdom and the United States. The company was formerly known as VASTox plc and changed its name to Summit Corporation Plc in July 2007. Summit Corporation plc was founded in 2003 and is headquartered in Abingdon, the United Kingdom.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Disease Drug Discovery Antibiotics Dementia Dystrophy Muscular Dystrophy Summit Duchenne Muscular Dystrophy Duchenne Cdi Clostridioides Difficile Clostridium Difficile Infection Clostridium Difficile
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 5.22 |
52 Week Low | 1.3 |
Average Volume | 2,265,160 |
200-Day Moving Average | 2.72 |
50-Day Moving Average | 4.15 |
20-Day Moving Average | 3.75 |
10-Day Moving Average | 3.75 |
Average True Range | 0.31 |
RSI (14) | 41.52 |
ADX | 10.61 |
+DI | 19.83 |
-DI | 26.91 |
Chandelier Exit (Long, 3 ATRs) | 3.70 |
Chandelier Exit (Short, 3 ATRs) | 4.19 |
Upper Bollinger Bands | 4.24 |
Lower Bollinger Band | 3.26 |
Percent B (%b) | 0.24 |
BandWidth | 25.96 |
MACD Line | -0.14 |
MACD Signal Line | -0.11 |
MACD Histogram | -0.028 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 3.82 | ||||
Resistance 3 (R3) | 3.80 | 3.67 | 3.76 | ||
Resistance 2 (R2) | 3.67 | 3.59 | 3.68 | 3.74 | |
Resistance 1 (R1) | 3.59 | 3.54 | 3.61 | 3.61 | 3.73 |
Pivot Point | 3.46 | 3.46 | 3.47 | 3.47 | 3.46 |
Support 1 (S1) | 3.38 | 3.38 | 3.40 | 3.40 | 3.27 |
Support 2 (S2) | 3.25 | 3.33 | 3.26 | 3.26 | |
Support 3 (S3) | 3.17 | 3.25 | 3.24 | ||
Support 4 (S4) | 3.19 |